Trial reportJournal of cosmetic dermatology2026
Twelve-Month Outcome of Nasolabial Fold Correction by a Novel Non-1,4-Butanediol Diglycidyl Ether, Click-Crosslinked, Long-Chain Hyaluronic Acid Product.
Trial report in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHyaluronic acid (HA) products used for nasolabial fold (NLF) correction are typically crosslinked with 1,4-Butanediol diglycidyl ether (BDDE) and contain high HA concentrations and short HA chains. These characteristics may contribute to increased stiffness, enhanced immune reactivity, and less natural aesthetic outcomes. A novel HA material utilizing click-chemistry for crosslinking to preserve long-chain structure and afford low HA concentration and minimal modification was developed as a potential alternative.
aimThe aim of this study was to evaluate the 12-month safety and clinical performance of a non-BDDE, click-chemistry crosslinked, long-chain HA compound (HLR-2, Hallura) for NLF correction.
methodsTwo prospective, open-label studies were conducted, one in Europe and the other in Israel. All subjects received HLR-2 injections and were followed for 12 months. Efficacy was assessed by the Wrinkle Severity Rating Scale, Global Aesthetic Improvement Scale, and patient satisfaction measures. Safety was monitored through reporting of adverse events (AE) and documentation of injection site reactions (ISR).
resultsSixty-two subjects (29 Israeli and 33 European) were included. Responder rates at 6 months were 90.7% and 86.4%, respectively, with improvements sustained throughout 12 months. Satisfaction levels remained high (≥ 94% at all time points). ISRs were mild and transient, with no serious or delayed-onset AEs, and favorable induction of collagen and elastin and enhanced tissue integration were documented.
conclusionHLR-2 demonstrated high efficacy, high patient satisfaction, and a favorable safety profile over 12 months. The product's distinctive composition and clinical performance support its use for aesthetic indications, with potential for broader therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.